The supplement industry is booming—but so are serious health issues tied to taking these pills and powders. Here’s what ...
MediWound has commenced a pivotal, multicentre Phase III VALUE trial to assess its bioactive debridement therapy, EscharEx, ...
Aging is a privilege, but it also brings risks—including an increased likelihood of developing age-related diseases including ...
Research has uncovered key differences in gene expression linked to inflammation, metabolism and cardioprotection. These findings could help inform the development of targeted therapies for ...
Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected in ...